vs
Side-by-side financial comparison of SOLESENCE, INC. (SLSN) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.
Xilio Therapeutics, Inc. is the larger business by last-quarter revenue ($13.7M vs $12.5M, roughly 1.1× SOLESENCE, INC.). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs 1.3%, a 74.4% gap on every dollar of revenue.
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
SLSN vs XLO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $12.5M | $13.7M |
| Net Profit | $163.0K | $10.4M |
| Gross Margin | 27.5% | — |
| Operating Margin | 1.5% | -86.5% |
| Net Margin | 1.3% | 75.7% |
| Revenue YoY | -0.7% | — |
| Net Profit YoY | 129.2% | 179.1% |
| EPS (diluted) | $0.00 | $-3.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $12.5M | $13.7M | ||
| Q3 25 | $14.6M | $19.1M | ||
| Q2 25 | $20.4M | $8.1M | ||
| Q1 25 | $14.6M | $2.9M | ||
| Q4 24 | $12.6M | — | ||
| Q3 24 | $16.9M | — | ||
| Q2 24 | $13.0M | — | ||
| Q1 24 | $9.9M | — |
| Q4 25 | $163.0K | $10.4M | ||
| Q3 25 | $-1.1M | $-16.3M | ||
| Q2 25 | $2.7M | $-15.8M | ||
| Q1 25 | $80.0K | $-13.3M | ||
| Q4 24 | $-559.0K | — | ||
| Q3 24 | $3.0M | — | ||
| Q2 24 | $856.0K | — | ||
| Q1 24 | $893.0K | — |
| Q4 25 | 27.5% | — | ||
| Q3 25 | 23.1% | — | ||
| Q2 25 | 28.9% | — | ||
| Q1 25 | 23.1% | — | ||
| Q4 24 | 22.0% | — | ||
| Q3 24 | 36.2% | — | ||
| Q2 24 | 28.7% | — | ||
| Q1 24 | 36.3% | — |
| Q4 25 | 1.5% | -86.5% | ||
| Q3 25 | -5.4% | -10.1% | ||
| Q2 25 | 9.4% | -177.7% | ||
| Q1 25 | 1.8% | -472.7% | ||
| Q4 24 | -1.8% | — | ||
| Q3 24 | 19.0% | — | ||
| Q2 24 | 8.0% | — | ||
| Q1 24 | 11.3% | — |
| Q4 25 | 1.3% | 75.7% | ||
| Q3 25 | -7.7% | -85.4% | ||
| Q2 25 | 13.1% | -196.0% | ||
| Q1 25 | 0.5% | -452.7% | ||
| Q4 24 | -4.4% | — | ||
| Q3 24 | 18.1% | — | ||
| Q2 24 | 6.6% | — | ||
| Q1 24 | 9.0% | — |
| Q4 25 | $0.00 | $-3.74 | ||
| Q3 25 | $-0.02 | $-0.11 | ||
| Q2 25 | $0.04 | $-0.16 | ||
| Q1 25 | $0.00 | $-0.18 | ||
| Q4 24 | $0.00 | — | ||
| Q3 24 | $0.04 | — | ||
| Q2 24 | $0.01 | — | ||
| Q1 24 | $0.02 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.3M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $17.6M | $35.3M |
| Total Assets | $50.1M | $154.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.3M | $137.5M | ||
| Q3 25 | $429.0K | $103.8M | ||
| Q2 25 | $4.1M | $121.6M | ||
| Q1 25 | $1.8M | $89.1M | ||
| Q4 24 | $1.4M | — | ||
| Q3 24 | $2.9M | — | ||
| Q2 24 | $2.4M | — | ||
| Q1 24 | $2.0M | — |
| Q4 25 | $17.6M | $35.3M | ||
| Q3 25 | $17.2M | $-8.1M | ||
| Q2 25 | $18.2M | $7.1M | ||
| Q1 25 | $15.2M | $10.7M | ||
| Q4 24 | $14.9M | — | ||
| Q3 24 | $15.2M | — | ||
| Q2 24 | $11.9M | — | ||
| Q1 24 | $5.0M | — |
| Q4 25 | $50.1M | $154.7M | ||
| Q3 25 | $54.0M | $133.7M | ||
| Q2 25 | $60.0M | $133.8M | ||
| Q1 25 | $57.0M | $103.7M | ||
| Q4 24 | $50.0M | — | ||
| Q3 24 | $48.0M | — | ||
| Q2 24 | $40.8M | — | ||
| Q1 24 | $38.5M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.8M | $-2.0M |
| Free Cash FlowOCF − Capex | — | $-2.1M |
| FCF MarginFCF / Revenue | — | -15.3% |
| Capex IntensityCapex / Revenue | — | 0.7% |
| Cash ConversionOCF / Net Profit | 11.16× | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.8M | $-2.0M | ||
| Q3 25 | $-2.5M | $-17.5M | ||
| Q2 25 | $-654.0K | $-14.5M | ||
| Q1 25 | $-7.2M | $29.0M | ||
| Q4 24 | $2.2M | — | ||
| Q3 24 | $4.2M | — | ||
| Q2 24 | $-565.0K | — | ||
| Q1 24 | $-3.9M | — |
| Q4 25 | — | $-2.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-14.9M | ||
| Q1 25 | — | $29.0M | ||
| Q4 24 | $-404.0K | — | ||
| Q3 24 | $2.8M | — | ||
| Q2 24 | $-1.0M | — | ||
| Q1 24 | $-3.9M | — |
| Q4 25 | — | -15.3% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -184.0% | ||
| Q1 25 | — | 988.3% | ||
| Q4 24 | -3.2% | — | ||
| Q3 24 | 16.6% | — | ||
| Q2 24 | -8.0% | — | ||
| Q1 24 | -39.9% | — |
| Q4 25 | — | 0.7% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 5.0% | ||
| Q1 25 | — | 0.8% | ||
| Q4 24 | 20.6% | — | ||
| Q3 24 | 8.3% | — | ||
| Q2 24 | 3.7% | — | ||
| Q1 24 | 0.9% | — |
| Q4 25 | 11.16× | -0.19× | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.25× | — | ||
| Q1 25 | -90.26× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.38× | — | ||
| Q2 24 | -0.66× | — | ||
| Q1 24 | -4.32× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
